#4
BioNTech (US Operations)
The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology.
Photos (1)
Comments on "BioNTech (US Operations)"
Create a free account or sign in to join the discussion.
Sign in to join the conversation